With value frameworks still in their infancy, Michael Kolodziej, MD, national medical director for oncology strategy at Aetna, doesn't see how his company can use them just yet. In fact, these frameworks may never be used by insurers, but only for shared decision making between the patient and provider.
With value frameworks still in their infancy, Michael Kolodziej, MD, national medical director for oncology strategy at Aetna, doesn't see how his company can use them just yet. In fact, these frameworks may never be used by insurers, but only for shared decision making between the patient and provider.
Transcript (slightly modified)
Does Aetna plan to leverage the value calculators and frameworks that are no available?
At the present time no. And I think part of that is because they are all works in progress. Now, I will say, and I have said this multiple times, I applaud everybody who is working in this space around their courage, in attempting to objectively define a way of measuring value: having worked in the clinical pathways space for a long time, that was basically the same thing. The better thing now is that people seem to have caught the virus of being interested in quantifying value, but there are some important things missing that make it really, really hard for me to totally embrace them.
The 2 most important things that are missing are the element of real-world evidence—and I think we need to support efforts to collect real-world evidence—and second of all, the patient voice is not adequately represented. I think those are solvable problems and as we look to the next set of iterations we will see attempts to incorporate them. But speaking from the insurance company point of view, I don't see a way that the insurance company is going to use them. But I do see a way that they are going to become an important component of shared decision making at the physician-patient level.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More